AstraZeneca agreed to buy Gracell Biotechnologies for a transaction value of $1.2 billion, as part of AstraZeneca’s efforts to grow its cell therapies business.

AstraZeneca agreed to buy Gracell Biotechnologies for a transaction value of $1.2 billion, as part of AstraZeneca’s efforts to grow its cell therapies business. https://ift.tt/3DohdTn